Accrued Liabilities

9 Months Ended

Sep. 30, 2018

Accrued Liabilities

Accrued Liabilities

3.Accrued Liabilities

Accrued liabilities consist of the following (in thousands):

	September 30,		December 31,
	2018		2017
Accrued compensation and other payroll liabilities	$	368	$	306
Workforce reduction severance		360		—
Legal costs		109		91
Accrued interest		42		38
Other research and development expenses		674		522
Other general and administrative expenses		32		53
Total	$	1,585	$	1,010

The workforce reduction severance resulted from the Company’s Board of Directors approval on September 18, 2018 of a workforce reduction involving 5 employees (or 33% of the workforce at that time) to lower costs and conserve cash resources in light of the previously announced request by the Food and Drug Administration (FDA) for additional pre-clinical data required in order to schedule an End of Phase 2 (EOP2) meeting for gemcabene in the Company’s target indications. Related expenses recognized during the quarter totaled approximately $1.3 million, of which approximately $0.6 million was recorded as general and administrative expense and $0.7 million was recorded as research and development expense. $360,000 remained unpaid at the end of the third quarter.